iShares MSCI South Korea ETF vs Johnson & Johnson — how do they compare? iShares MSCI South Korea ETF trades at $175.99, while Johnson & Johnson trades at $259.89 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while iShares MSCI South Korea ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals.
| EWY | JNJ | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $267.24 |
52-Week Low | $71.22 | $172.78 |
Market Cap | — | $626.09B |
Volume | — | 6,156,228 |
Enterprise Value | — | $654.37B |
Dividend Yield | — | 2.06% |
Signals from Pluang's Aura AI — not financial advice
EWY trades at $175.21, up 7.41% over the past 24 hours, showing strong momentum amid volatile South Korean market conditions. The ETF exhibits mixed technical signals with bullish moving averages but neutral oscillators, while support and resistance levels indicate potential consolidation between $166 and $172. Recent news highlights significant volatility in South Korean equities driven by AI and semiconductor sector turbulence, with foreign investors rotating capital away from Asian markets.
The outlook remains cautious as EWY faces headwinds from concentrated exposure to South Korea's volatile semiconductor sector, though government support initiatives and Goldman Sachs' bullish 90% upside projection offer potential catalysts. Key risks include continued foreign capital outflows, leveraged ETF speculation concerns, and dependence on AI-driven market swings that have caused recent sharp declines in major holdings like Samsung and SK Hynix.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →